logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9109025 B1

PDFFull Text
Date of Patent:
Aug. 18, 2015

Filed:

Jun. 27, 2014

Anti-rspo2 antibodies

Applicant:

Oncomed Pharmaceuticals, Inc., Redwood City, CA (US);

Inventors:

Austin L. Gurney, San Francisco, CA (US);

Fumiko Takada Axelrod, Palo Alto, CA (US);

Timothy Charles Hoey, Hillsborough, CA (US);

Cecile Chartier-Courtaud, Palo Alto, CA (US);

Assignee:

OncoMed Pharmaceuticals, Inc., Redwood City, CA (US);

Attorney:

Sterne, Kessler, Goldstein & Fox, P.L.L.C.

Primary Examiner:

Christine J Saoud

Assistant Examiner:

Jon M Lockard

Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2863 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3046 (2013.01); C07K 16/3069 (2013.01); G01N 33/57415 (2013.01); G01N 33/57423 (2013.01); G01N 33/57449 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

Find Patent Forward Citations

Loading…